Q-omics provides the consensus-scored RXYLT1 profile across patient tissues and cancer cell-line models. RXYLT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RXYLT1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RXYLT1 RNA expression shows 18,990 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, HNSC, and UVM as cancer lineages where RXYLT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RXYLT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RXYLT1 survival associations across molecular data types. RXYLT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RXYLT1 RNA expression–survival associations across cancer types. High RXYLT1 expression shows unfavorable associations in LUAD, LIHC, KIRP, LGG and HNSC, but favorable associations in UCS. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RXYLT1 RNA expression.
This table summarizes RXYLT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RXYLT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RXYLT1 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LUAD, LIHC and STAD. The HNSC box plot shows higher RXYLT1 RNA expression in tumor versus normal tissue (log2 FC = +0.660, t-test p < 0.001).
This table shows molecular features associated with RXYLT1 in patient tissues and cancer cell lines. In patient samples, RXYLT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RXYLT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
